共 50 条
- [32] Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)BLOOD, 2015, 126 (23)Zeidan, Amer M.Long, Jessica B.Hall, JaneWang, RongHuntington, Scott F.Abel, GregoryPrebet, ThomasPodoltsev, Nikolai A.Gross, Cary P.Gore, Steven D.Ma, XiaomeiDavidoff, Amy J.
- [33] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDSCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324Watts, JustinAdes, LionelRadinoff, AtanasArnan Sangerman, MontserratCerrano, MarcoFont Lopez, PatriciaZeidner, JoshuaCampelo, Maria DiezGraux, CarlosLiesveld, JaneSelleslag, DominikTzvetkov, NikolayFram, Robert J.Zhao, DanBell, JillFriedlander, SharonFaller, Douglas V.Sekeres, Mikkael A.
- [34] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic SyndromesCANCER, 2017, 123 (06) : 994 - 1002Garcia-Manero, GuillermoMontalban-Bravo, GuillermoBerdeja, Jesus G.Abaza, YasminJabbour, EliasEssell, JamesLyons, Roger M.Ravandi, FarhadMaris, MichaelHeller, BrianDeZern, Amy E.Babu, SunilWright, DavidAnz, BertrandBoccia, RalphKomrokji, Rami S.Kuriakose, PhilipReeves, JamesSekeres, Mikkael A.Kantarjian, Hagop M.Ghalie, RichardRoboz, Gail J.
- [35] Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeLEUKEMIA & LYMPHOMA, 2016, 57 (03) : 609 - 615Narayan, RupaGarcia, Jacqueline S.Percival, Mary-Elizabeth M.Berube, CarolineCoutre, SteveGotlib, JasonGreenberg, PeterLiedtke, MichaelaHewitt, RhondaRegan, KathleenWilliamson, CharlesDoykan, CamilleCardone, Michael H.McMillan, AlexMedeiros, Bruno C.
- [36] PHARMACOKINETICS (PK) OF SUBCUTANEOUS (SC) AZACITIDINE (AZA) IN CHINESE SUBJECTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) FROMA PHASE II, OPEN-LABEL STUDY.CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S81 - S81Laille, E.Xiao, Z.Du, X.Dong, Q.Songer, S.Beach, C.
- [37] Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)BLOOD, 2022, 140 : 8821 - 8822Xiao, ZhijianChang, ChunkangLi, QiubaiYan, XiaojingQin, TiejunTong, HongyanZhang, YuDai, MinHe, YanjieWeng, JianyuLi, JianGao, SujunFu, RongWei, XudongHe, AiliRen, JinhaiWu, TongDu, XinZhang, YanniXu, KeWang, ZhengyiYang, MichelleZhu, Andrew
- [38] A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S5 - S5Daver, NavalLiu, KeWerneke, ScottRustia, EvelynRamsingh, GiriVyas, Paresh
- [39] Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic SyndromeBLOOD, 2020, 136Chien, Kelly S.Borthakur, GautamNaqvi, KiranDaver, NavalBravo, Guillermo MontalbanCortes, Jorge E.DiNardo, Courtney D.Jabbour, EliasAlvarado, YesidAndreeff, MichaelBose, PrithvirajJain, NitinSheppard, KimberlyKlingner-Winton, CheriPierce, Sherry A.Dong, Xiao QinSoltysiak, Kelly A.Kantarjian, Hagop M.Garcia-Manero, Guillermo
- [40] A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine plus Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other ComorbiditiesBLOOD, 2014, 124 (21)Garcia-Manero, GuillermoHuang, XuelinCabrero, MonicaDiNardo, Courtney D.Pemmaraju, NaveenDaver, Naval G.Borthakur, GautamWierda, William G.Kadia, TapanAlvarado, YesidCortes, Jorge E.Jain, NitinRavandi, FarhadJabbour, EliasBrandt, MarkSneed, TroySukholutsky, VictoriaPierce, SherryBohannan, ZacharyKantarjian, Hagop M.